Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. (HCAT) director Gallagher Duncan received an award of 4,970 restricted stock units (RSUs) that vested in full on September 1, 2025. Each RSU converts into one share of common stock; the filing reports no cash price for the award and shows Mr. Duncan beneficially owns 118,252 shares following the vesting. The Form 4 was signed by an attorney-in-fact on September 5, 2025 and reflects the director relationship of the reporting person.
Health Catalyst, Inc. (HCAT) reported a Form 144 notice for an intended sale of 6,175 common shares, with an aggregate market value of $20,377.50, scheduled approximately for 09/05/2025. The shares were acquired as restricted stock units (RSUs) on 09/01/2025 and recorded as paid on the same date. The filing shows there are 70,373,625 shares outstanding for the issuer and names Morgan Stanley Smith Barney LLC as the broker for the proposed sale on NASDAQ. The Form 144 also discloses a recent sale by the same person of 3,138 shares on 09/02/2025 for $10,552.15. The filer represents no undisclosed material adverse information.
Ross David Coy, Chief Technology & Product Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,360 shares of common stock on 09/02/2025 at an average price of $3.3627 per share. The filing states the sale was a sell-to-cover transaction to satisfy tax withholding obligations tied to vesting restricted stock units and was not a discretionary trade. After the transaction the reporting person beneficially owns 204,219 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025.
Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 4,578 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax-withholding obligations tied to the vesting of restricted stock units. The filing lists 375,087 shares beneficially owned by Freeman after the transaction. The disclosure clarifies this was a sell-to-cover transaction required by the issuer's equity plan and was not a voluntary sale by the reporting person.
Health Catalyst, Inc. (HCAT) reporting officer Jason Alger, the company's Chief Financial Officer, reported a mandatory sale of common stock to satisfy tax withholding from vested restricted stock units. The Form 4 shows a disposition of 2,613 shares on 09/02/2025 at a reported price of $3.3627 per share, leaving the reporting person with 267,033 shares beneficially owned after the transaction. The filing was submitted as an individual Form 4 and signed on behalf of the reporting person by an attorney-in-fact on 09/04/2025. The filing clarifies this was a non-discretionary "sell to cover" required by the issuer's equity plan and not an independent trading decision.
Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc. (HCAT), reported a sale of 3,663 shares of the issuer's common stock on 09/02/2025 at a price of $3.3627 per share. The filing states this sale was a mandatory "sell to cover" to satisfy tax-withholding obligations arising from the vesting of restricted stock units and not a discretionary trade. After the transaction, the reporting person beneficially owned 198,367 shares. The Form 4 was signed by Benjamin Landry as attorney-in-fact on 09/04/2025. The report documents an insider compliance action rather than an open-market decision.
Burton D. Burton, Chief Executive Officer and Director of Health Catalyst, Inc. (HCAT), reported a non-discretionary sell-to-cover transaction on 09/02/2025. The filing shows 8,335 shares were sold at $3.3627 per share to satisfy tax withholding obligations arising from vested restricted stock units; this was a mandatory sale under the issuer's equity plan rather than a voluntary trade. After the transaction the reporting person beneficially owns 1,448,814 shares. No derivative securities were reported in this filing and the Form 4 was signed by an attorney-in-fact on 09/04/2025.
Health Catalyst insider sale tied to RSU tax withholding. Chief People Officer Linda Llewelyn reported a sale of 2,854 shares of Health Catalyst, Inc. (HCAT) on 09/02/2025 at $3.3627 per share. The filing states this sale was a mandated "sell-to-cover" to satisfy tax withholding on vested restricted stock units, not a discretionary trade. After the transaction, the reporting person beneficially owned 153,025 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,138 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax withholding from the vesting of restricted stock units. After the transaction, he beneficially owned 147,987 shares. The filing specifies this was a sell-to-cover required under the issuer's equity incentive plan and not a voluntary trade by the reporting person. The Form 4 is signed and dated 09/04/2025.
Health Catalyst, Inc. director Spencer Justin was granted 68,572 restricted stock units (RSUs) on 09/01/2025 under the company's 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock and the award was reported with a $0.00 per-share price, consistent with typical equity awards to directors.
The RSUs vest under the Non-Employee Director Compensation Policy: 33.33% vests on 09/01/2026 and the remaining 66.67% vests in two equal annual installments thereafter. The filing was made by one reporting person and signed by an attorney-in-fact on 09/03/2025.